Clinical Trial Update: Safety Study of Grass Pollen-derived Peptides to Treat Seasonal Allergic Rhinoconjunctivitis [Phase 1, Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 1/2 safety trial evaluating grass pollen-derived peptides for seasonal allergic rhinitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Seasonal Allergic Rhinitis

Drugs mentioned

• Grass pollen-derived peptides

Snippet

Sponsor: BioTech Tools S.A. | Conditions: Seasonal Allergic Rhinoconjunctivitis | Phase 1, Phase 2 | Status: COMPLETED